Metabolic risk factors of cognitive impairment in young women with major psychiatric disorder
Authors:
Open Access
- 29 July 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 880031
Abstract
Background: Cognitive performance improves clinical outcomes of patients with major psychiatric disorder (MPD), but is impaired by hyperglycemia. Psychotropic agents often induce metabolism syndrome (MetS). The identification of modifiable metabolic risk factors of cognitive impairment may enable targeted improvements of patient care.Objective: To investigate the relationship between MetS and cognitive impairment in young women with MPD, and to explore risk factors.Methods: We retrospectively studied women of 18–34 years of age receiving psychotropic medications for first-onset schizophrenia (SCH), bipolar disorder (BP), or major depressive disorder (MDD). Data were obtained at four time points: presentation but before psychotropic medication; 4–8 and 8–12 weeks of psychotropic therapy; and enrollment. MATRICS Consensus Cognitive Battery, (MCCB)—based Global Deficit Scores were used to assess cognitive impairment. Multiple logistic analysis was used to calculate risk factors. Multivariate models were used to investigate factors associated with cognitive impairment.Results: We evaluated 2,864 participants. Cognitive impairment was observed in 61.94% of study participants, and was most prevalent among patients with BP (69.38%). HbA1c within the 8–12 week-treatment interval was the most significant risk factor and highest in BP. Factors in SCH included pre-treatment waist circumference and elevated triglycerides during the 8–12 weeks treatment interval. Cumulative dosages of antipsychotics, antidepressants, and valproate were associated with cognitive impairment in all MPD subgroups, although lithium demonstrated a protect effect (all P < 0.001).Conclusions: Cognitive impairment was associated with elevated HbA1c and cumulative medication dosages. Pre-treatment waist circumference and triglyceride level at 8–12 weeks were risk factors in SCH. Monitoring these indices may inform treatment revisions to improve clinical outcomes.Keywords
This publication has 72 references indexed in Scilit:
- Psychoanalysis and social cognitive neuroscience: A new framework for a dialogueJournal of Physiology-Paris, 2011
- Rethinking the cognitive revolution from a neural perspective: How overuse/misuse of the term ‘cognition’ and the neglect of affective controls in behavioral neuroscience could be delaying progress in understanding the BrainMindNeuroscience & Biobehavioral Reviews, 2011
- Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophreniaPsychological Medicine, 2011
- Bipolar disorder and metabolic syndrome: An international perspectiveJournal of Affective Disorders, 2010
- The Beck Cognitive Insight Scale (BCIS): translation and validation of the Taiwanese versionBMC Psychiatry, 2010
- Women, Aging, and SchizophreniaJournal of Women & Aging, 2007
- The Consortium on the Genetics of Schizophrenia: Neurocognitive EndophenotypesSchizophrenia Bulletin, 2006
- Antipsychotic medication: effects on regulation of glucose and lipidsExpert Opinion on Pharmacotherapy, 2001
- Neuropsychological Differences Between First-Admission Schizophrenia and Psychotic Affective DisordersAmerican Journal of Psychiatry, 2000
- A self‐report Insight Scale for psychosis: reliability, validity and sensitivity to changeActa Psychiatrica Scandinavica, 1994